Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03213678 · OUTCOME

Pharmacokinetic (PK) of Samotolisib, Area Under the Curve (AUC).

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
h*μg/mL
Interval / dispersion
Standard Deviation
Time frame
Up to day 15 of cycle 1

What was measured

The mean (sd) of the AUC

Analysis population: Three of the enrolled patients had PK data available for analysis

Groups in this outcome

Treatment (Samotolisib)

Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Samotolisib)3

Reported measurements

Source class 1
Values in h*μg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Treatment (Samotolisib)23231006Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1006
        value
        2323
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
The mean (sd) of the AUC
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.
    id
    OG000
    title
    Treatment (Samotolisib)
param Type
MEAN
population Description
Three of the enrolled patients had PK data available for analysis
reporting Status
POSTED
time Frame
Up to day 15 of cycle 1
title
Pharmacokinetic (PK) of Samotolisib, Area Under the Curve (AUC).
type
SECONDARY
unit Of Measure
h*μg/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice